--- title: "Xishan Science&Technology has completed its buyback, spending a total of 197 million yuan to repurchase 6.296% of its shares" type: "News" locale: "en" url: "https://longbridge.com/en/news/232397944.md" description: "According to the announcement from Xishan Science&Technology on the Zhitong Finance APP, the company has completed its share repurchase, having repurchased a total of 3.1245 million shares through centralized bidding, accounting for 6.2960% of the company's total share capital, with a total payment of RMB 197 million (excluding transaction fees)" datetime: "2025-03-19T10:56:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/232397944.md) - [en](https://longbridge.com/en/news/232397944.md) - [zh-HK](https://longbridge.com/zh-HK/news/232397944.md) generator: "portal-rs" --- # Xishan Science&Technology has completed its buyback, spending a total of 197 million yuan to repurchase 6.296% of its shares According to the Zhitong Finance APP, Xishan Science&Technology (688576.SH) announced that the company has completed its share repurchase, having repurchased a total of 3.1245 million shares through centralized bidding, accounting for 6.2960% of the company's total share capital, with a total payment of RMB 197 million (excluding transaction fees) ### Related Stocks - [688576.CN](https://longbridge.com/en/quote/688576.CN.md) ## Related News & Research - [KINGSOFT Interim Net Profit Up 100.8% YoY to RMB1.639 Billion; No Interim Dividend](https://longbridge.com/en/news/296417569.md) - [Nurture plans new production site as Oosterbeek facility hits capacity limits](https://longbridge.com/en/news/296582570.md) - [PEB: Draft Medicare coverage for Cxbladder tests marks a pivotal step toward renewed growth](https://longbridge.com/en/news/296426151.md) - [Britain's JD Sports cuts profit outlook as U.S. sales slump](https://longbridge.com/en/news/296444248.md) - [Alma News Media joins SPUR coalition on AI licensing standards for publishers](https://longbridge.com/en/news/296579604.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**